United Kingdom antirheumatic drugs market was valued at US$1,109.524 million in 2019. The market in the United Kingdom is projected to show a nominal growth over the next five years on account of the high prevalence of rheumatic diseases in the country coupled with the presence of a world-class healthcare sector of the country. According to the United Kingdom National Health Service, more than 10 million people in the country suffer from arthritis and numerous conditions. This, in turn, is anticipated to significantly drive the demand for various types of anti-rheumatic drugs and thus positively impact the market growth in the country in the coming years. Furthermore, the growing healthcare expenditure further enables the citizens to avail costly treatments and medicines which is also projected to positively impact the market growth in the United Kingdom throughout the forecast period.
Additionally, with the growing number of geriatric people, aged 65 years and above in the United Kingdom, the number of age-associated diseases such as joint pains, back pain, and rheumatoid arthritis among others, hence the market for various types of antirheumatic drugs will also continue to soar due to their requirement for disease treatment. According to the World Bank estimates, the geriatric population (65 years of age or older) in the United Kingdom has grown from a population size of 11.706 million in 2015 to a population size of 12.231 million in 2018.
The United Kingdom antirheumatic drugs market has been segmented on the basis of the type of disease, type of molecule, and sales channel. On the basis of the type of disease, the market has been classified on the basis of osteoarthritis, rheumatoid arthritis, gout, lupus, and others.By the type of molecule, the market has been segmented on the basis of pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC).